RanaRamziMcKayMD

Oncology • San Diego, CA

Physician

Join to view full profile

Dr. McKay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McKay's full profile

Already have an account?

Office
200 W Arbor Dr
San Diego, CA 92103
Phone+1 800-926-8273

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Johns Hopkins UniversityResidency, Internal Medicine, 2008 - 2011
University of Florida College of MedicineClass of 2008

Certifications & Licensure

CA State Medical License 2016 - 2026
MA State Medical License 2011 - 2018

Clinical Trials

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
Terminated
Phase 1, Phase 2
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis Start of enrollment: 2019 Feb 04
Suspended
Phase 1, Phase 2
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Start of enrollment: 2018 Nov 26
Active, not recruiting
Phase 2, Phase 3
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Start of enrollment: 2020 Jul 29
Recruiting
Phase 2
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Start of enrollment: 2017 Dec 28
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Improving Germline Testing in At-Risk Patients With Prostate Cancer Start of enrollment: 2022 Sep 27
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations Start of enrollment: 2023 Feb 01
Recruiting
Phase 2
Roles: Contact, Sponsor-Investigator, Principal Investigator
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2023 Feb 02
Recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

94 citations
Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma
Rana R. McKay, Gustavo Enrique Rodriguez, Xun Lin, Marina D. Kaymakcalan, Ole-Petter R. Hamnvik
Clinical Cancer Research. 2015-02-27
93 citations
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
Edward M Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas
Journal of the National Comprehensive Cancer Network. 2023-10-01
102 citations
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen
Journal of Clinical Oncology. 2023-01-01

Journal Articles

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma
Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology

Authored Content

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020

Press Mentions

First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney CancerOctober 24th, 2024
ESMO: Despite Survival Miss, Exelixis Presses on with FDA Prostate Cancer Bid as Ipsen Scraps EU PlanSeptember 16th, 2024
NCCN Clinical Practice Guidelines in Oncology: 2023 UpdatesMay 19th, 2023
Join now to see all